Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure
Yıl: 2022 Cilt: 55 Sayı: 1 Sayfa Aralığı: 52 - 57 Metin Dili: İngilizce DOI: 10.5505/aot.2022.47113 İndeks Tarihi: 11-07-2022
Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure
Öz: Introduction: One of the major causes of morbidity and mortality of autologous hematopoietic stem cell transplantation (ASCT) is infections during prolonged neutropenia. In this study, we aimed to investigate the effect of prophylactic G-CSF use in ASCT patient on the frequency of infection, duration of neutrophil engraftment and neutropenia, length of hospital stay and transplant-related morbidity and mortality.
Methods: G-CSF has been routinely used after autologous stem cell transplantation in our unit for 3 years since February 2014. In this study, three years before and after the application consecutive auto-HSCT data were collected retrospectively. In addition to routine antimicrobial prophylaxis, In the group receiving G-CSF, 5mcg/kg/day G-CSF sc was started from fifth day and application was continued until neutrophil engraftment.
Results: A total of 226 patients (129 males, 97 females) were included in the study. In patients receiving prophylactic G-CSF, neutrophil engraftment was earlier [13 (9-23) and 12 (10-22) days], and the duration of neutropenia [11 (5-23) and 8 (5-19) days] was shorter (p <0.001). In the ASCT series prophylactic use of G-CSF showed that reduced the duration of neutropenia and decreased in neutropenic fever frequency.
Discussion and Conclusion: Transplant-related mortality (TRM) and infection-related mortality analyzes were not very significant due to the low level of event (p> 0.05)
Anahtar Kelime: Otolog Kök Hücre Nakli̇ ni̇ n Bi̇ r Parçasi Olarak Standart Profi̇ lakti̇ k G-CSF Uygulanmasi
Öz: Giriş ve Amaç: Otolog hematopoietik kök hücre transplantasyonunun (ASCT) morbidite ve mortalitesinin başlica nedenlerinden biri, uzun süreli nötropeni sirasindaki enfeksiyonlardir. Bu çalişmada ASCT hastalarinda profilaktik G-CSF kullaniminin enfeksiyon sikliği, nötrofil engraftmani ve nötropeni süresi, hastanede kaliş süresi ve nakille ilişkili morbidite ve mortalite üzerine etkisini araştirmayi amaçladik.
Yöntem ve Gereçler: G-CSF, birimimizde Şubat 2014'ten itibaren 3 yildir otolog kök hücre nakli sonrasi rutin olarak kullanilmaktadir. Bu çalişmada, uygulamadan üç yil önce ve sonra ardişik oto-HSCT verileri geriye dönük olarak toplanmiştir. Rutin antimikrobiyal profilaksiye ek olarak, G-CSF alan grupta beşinci günden itibaren 5 mcg/kg/gün G-CSF sc başlandi ve nötrofil engraftrasyonuna kadar uygulamaya devam edildi.
Bulgular: Çalişmaya toplam 226 hasta (129 erkek, 97 kadin) dahil edildi. Profilaktik G-CSF alan hastalarda nötrofil engraftmani daha erkendi [13 (9-23) ve 12 (10-22) gün] ve nötropeni süresi [11 (5-23) ve 8 (5-19) gün] daha kisaydi (p <0.001). ASCT serisinde profilaktik olarak G-CSF kullaniminin nötropeni süresini azalttiğini ve nötropenik ateş sikliğini azalttiğini göstermiştir.
Tartışma ve Sonuç: Organ nakline bağli ölüm orani (TİM) ve enfeksiyona bağli ölüm orani analizleri, olay seviyesinin düşük olmasi nedeniyle çok anlamli değildi (p> 0.05).
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Trivedi M, S Martinez, S Corringham. Optimal use of GCSF administration after hematopoietic SCT. Bone Marrow Transplantation 2009; 43, 895–908
- 2. Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265–271.
- 3. Afessa B, Peters SG. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med 2006; 27: 297–309
- 4. Smith LA, Wright-Kanuth MS. Complications and risks in hematopoietic stem cell transplant patients. Clin Lab Sci 2001; 14: 118–124.
- 5. Richard S, Schuster MW. Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep 2002; 1: 103–109.
- 6. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program 2003, 419–437.
- 7. Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood 2006; 107: 3430–3435.
- 8. Esser M, Brunner H. Economic Evaluations of Granulocyte Colony-Stimulating Factor In the Prevention and Treatment of Chemotherapy-Induced Neutropenia. Pharmaco-economics 2003; 21: 1295-1313
- 9. Mehta HM, Malandra M, Seth J. Corey G-CSF and GMCSF in Neutropenia. J Immunol. 2015; 195: 1341–1349.
- 10. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheralblood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323–1327.
- 11. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheralblood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451–457.
- 12. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80–85.
- 13. Stroncek D, Shawker T, Follmann D, Leitman SF. GCSF- induced spleen size changes in peripheral blood progenitor cell donors. Transfusion.2003; 43: 609-13.
- 14. Alshamrani MA, Al-Foheidi M, Abdulrahim AH. Granulocyte Colony Stimulating Factor (G-CSF) Induced Splenic Infarction in Breast Cancer Patient Treated with Dose-Dense Chemotherapy Regimen. Case Rep Oncol Med. 2019; 2019: 8174986.
- 15. Clark RE, Shlebak AA, Creagh MD. Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective. Leuk Lymphoma. 1994; 16: 141-6
- 16. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheralblood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol. 1995; 13: 1323-7
- 17. Ghalaut PS, Sen R, Dixit G. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia. J Assoc Physicians India. 2008; 56: 942-4.
- 18. Peters WP, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C, Kurtzberg J. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (GCSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood. 1993; 81: 1709-19.
- 19. Ener RA, Meglathery SB, Cuhaci B, Topolsky D, Styler MJ, Crilley P, Brodsky I, Kahn SB, King RS. Use of granulocyte colony-stimulating factor after high-dose chemotherapy and autologous peripheral blood stem cell transplantation: what is the optimal timing? Am J Clin Oncol. 2001; 24: 19-25.
- 20. Torres-Gomez A, Jimenez MA, Alvarez MA et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study. Ann Hematol 1995; 71: 65–70
- 21. Paul M, Ram R, Kugler E, Farbman L, Peck A, Leibovici L, Lahav M, Yeshurun M, Shpilberg O, Herscovici C, Wolach O, Itchaki G, Bar-Natan M, Vidal L, Gafter-Gvili A, Raanani P. Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial. Am J Hematol. 2014; 89: 243–248
- 22. Khwaja A, Mills W, Leveridge AH, Goldstone AH, Linch DC. Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. Bone Marrow Transplant. 1993; 11: 479–482
- 23. Linch DC, Milligan DW, Winfield DA, G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial, Br J Haematol. 1997; 99: 933-8.
- 24. Gisselbrecht C, Prentice HG, Bacigalupo A, Placebocontrolled phase III trial of lenograstim in bone-marrow transplantation. Lancet. 1994; 343: 696-700.
- 25. Brice P, Godin S, Libert O. Effect of lenograstim on the cost of autologous bone marrow transplantation. A preliminary communication. Pharmacoeconomics. 1995; 7: 238-41
- 26. Sallerfors B, Olofsson T, Lenhoff S. Granulocytemacrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients. Bone Marrow Transplant. 1991; 8: 191-5
| APA | AYDIN KAYNAR L, OZKURT Z, Can F, yegin z, GUZEL TUNCCAN O, Yağcı M (2022). Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure. , 52 - 57. 10.5505/aot.2022.47113 |
| Chicago | AYDIN KAYNAR LALE,OZKURT ZÜBEYDE NUR,Can Ferda,yegin zeynep arzu,GUZEL TUNCCAN OZLEM,Yağcı Münci Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure. (2022): 52 - 57. 10.5505/aot.2022.47113 |
| MLA | AYDIN KAYNAR LALE,OZKURT ZÜBEYDE NUR,Can Ferda,yegin zeynep arzu,GUZEL TUNCCAN OZLEM,Yağcı Münci Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure. , 2022, ss.52 - 57. 10.5505/aot.2022.47113 |
| AMA | AYDIN KAYNAR L,OZKURT Z,Can F,yegin z,GUZEL TUNCCAN O,Yağcı M Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure. . 2022; 52 - 57. 10.5505/aot.2022.47113 |
| Vancouver | AYDIN KAYNAR L,OZKURT Z,Can F,yegin z,GUZEL TUNCCAN O,Yağcı M Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure. . 2022; 52 - 57. 10.5505/aot.2022.47113 |
| IEEE | AYDIN KAYNAR L,OZKURT Z,Can F,yegin z,GUZEL TUNCCAN O,Yağcı M "Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure." , ss.52 - 57, 2022. 10.5505/aot.2022.47113 |
| ISNAD | AYDIN KAYNAR, LALE vd. "Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure". (2022), 52-57. https://doi.org/10.5505/aot.2022.47113 |
| APA | AYDIN KAYNAR L, OZKURT Z, Can F, yegin z, GUZEL TUNCCAN O, Yağcı M (2022). Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure. ACTA ONCOLOGICA TURCICA, 55(1), 52 - 57. 10.5505/aot.2022.47113 |
| Chicago | AYDIN KAYNAR LALE,OZKURT ZÜBEYDE NUR,Can Ferda,yegin zeynep arzu,GUZEL TUNCCAN OZLEM,Yağcı Münci Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure. ACTA ONCOLOGICA TURCICA 55, no.1 (2022): 52 - 57. 10.5505/aot.2022.47113 |
| MLA | AYDIN KAYNAR LALE,OZKURT ZÜBEYDE NUR,Can Ferda,yegin zeynep arzu,GUZEL TUNCCAN OZLEM,Yağcı Münci Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure. ACTA ONCOLOGICA TURCICA, vol.55, no.1, 2022, ss.52 - 57. 10.5505/aot.2022.47113 |
| AMA | AYDIN KAYNAR L,OZKURT Z,Can F,yegin z,GUZEL TUNCCAN O,Yağcı M Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure. ACTA ONCOLOGICA TURCICA. 2022; 55(1): 52 - 57. 10.5505/aot.2022.47113 |
| Vancouver | AYDIN KAYNAR L,OZKURT Z,Can F,yegin z,GUZEL TUNCCAN O,Yağcı M Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure. ACTA ONCOLOGICA TURCICA. 2022; 55(1): 52 - 57. 10.5505/aot.2022.47113 |
| IEEE | AYDIN KAYNAR L,OZKURT Z,Can F,yegin z,GUZEL TUNCCAN O,Yağcı M "Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure." ACTA ONCOLOGICA TURCICA, 55, ss.52 - 57, 2022. 10.5505/aot.2022.47113 |
| ISNAD | AYDIN KAYNAR, LALE vd. "Standart Prophylactic Granulocyte Colony Stimulating Factor Usage as a Part of Autologous Stem Cell Transplantati̇ on Procedure". ACTA ONCOLOGICA TURCICA 55/1 (2022), 52-57. https://doi.org/10.5505/aot.2022.47113 |
